PDCD1 and renal cell carcinoma: One, by Labadie et al., categorized their 90 RCC subjects by either exhibiting primary response to ICI (i.e., patients who had received at least one dose of anti-PD-1 or anti-PD-L1 [pembrolizumab, nivolumab, atezolizumab]) or primary resistance to ICI.